Advisors Asset Management, Inc. Ultragenyx Pharmaceutical Inc. Transaction History

Advisors Asset Management, Inc.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 16, 2020	SELL	$72.98 - $90.0 $538,300 - $663,840	-7,376 Closed	0 $0
Q2 2020 Aug 12, 2020	SELL	$46.91 - $78.22 $255,331 - $425,751	-5,443 Reduced 42.46%	7,376 $577,000
Q1 2020 May 15, 2020	SELL	$33.8 - $62.9 $22,578 - $42,017	-668 Reduced 4.95%	12,819 $570,000
Q4 2019 Feb 14, 2020	SELL	$36.08 - $45.83 $14,395 - $18,286	-399 Reduced 2.87%	13,487 $576,000
Q3 2019 Nov 14, 2019	SELL	$42.5 - $63.11 $34,425 - $51,119	-810 Reduced 5.51%	13,886 $594,000
Q2 2019 Aug 14, 2019	SELL	$54.93 - $74.36 $24,993 - $33,833	-455 Reduced 3.0%	14,696 $933,000
Q1 2019 May 15, 2019	SELL	$39.87 - $69.36 $11,243 - $19,559	-282 Reduced 1.83%	15,151 $1.05 Million
Q4 2018 Jan 31, 2019	BUY	$38.89 - $77.3 $152,448 - $303,016	3,920 Added 34.05%	15,433 $671,000
Q3 2018 Nov 15, 2018	BUY	$71.81 - $90.15 $657,635 - $825,593	9,158 Added 388.87%	11,513 $879,000
Q2 2018 Aug 22, 2018	SELL	$48.54 - $85.31 $845,372 - $1.49 Million	-17,416 Reduced 88.09%	2,355 $181,000
Q2 2018 Aug 15, 2018	BUY	$48.54 - $85.31 $959,684 - $1.69 Million	19,771 New	19,771 $181,000

329

85.9M

520K

406K

Ticker RARE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,036,896
Market Cap $3.18B
Description
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...

Get notified when there are updates to the investment portfolio of Advisors Asset Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Advisors Asset Management, Inc. with notifications on news.